---
---

# 42 U.S.C., USLM ref /us/usc/t42/s1395w–153

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../../..//us/usc/t42/ch7/schXVIII/ptD/spt5/m__us_usc_t42_s1395w–152.md) | [Next](./../../../../../../..//us/usc/t42/ch7/schXVIII/ptD/spt5/m__us_usc_t42_s1395w–154.md) | [Root of Title](./../../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395w%E2%80%93153)

## § 1395w–153. Condition for coverage of drugs under this part

    (a) __In general__ 

    In order for coverage to be available under this part for covered part D drugs (as defined in [section 1395w–102(e) of this title][/us/usc/t42/s1395w–102/e]) of a manufacturer, the manufacturer must—

        (1) participate in the Medicare coverage gap discount program under [section 1395w–114a of this title][/us/usc/t42/s1395w–114a];

        (2) have entered into and have in effect an agreement described in subsection (b) of such section with the Secretary; and

        (3) have entered into and have in effect, under terms and conditions specified by the Secretary, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of such section.

    (b) __Effective date__ 

        Subsection (a) shall apply to covered part D drugs dispensed under this part on or after January 1, 2011.

    (c) __Authorizing coverage for drugs not covered under agreements__ 

    Subsection (a) shall not apply to the dispensing of a covered part D drug if—

        (1) the Secretary has made a determination that the availability of the drug is essential to the health of beneficiaries under this part; or

        (2) the Secretary determines that in the period beginning on January 1, 2011, and  <sup>\[1\]</sup>  <sup><sup> 1 So in original. Probably should be followed by “ending on”. </sup></sup>  December 31, 2011, there were extenuating circumstances.

    (d) __Definition of manufacturer__ 

        In this section, the term “manufacturer” has the meaning given such term in [section 1395w–114a(g)(5) of this title][/us/usc/t42/s1395w–114a/g/5].

([Aug. 14, 1935, ch. 531][/us/act/1935-08-14/ch531], title XVIII, § 1860D–43, as added [Pub. L. 111–148, title III][/us/pl/111/148/tIII], § 3301(a), Mar. 23, 2010, [124 Stat. 461][/us/stat/124/461]; amended [Pub. L. 111–152, title I][/us/pl/111/152/tI], § 1101(b)(1), Mar. 30, 2010, [124 Stat. 1037][/us/stat/124/1037].)

 __Amendments__ 

    2010—Subsec. (b). [Pub. L. 111–152][/us/pl/111/152], § 1101(b)(1)(A), substituted “January 1, 2011” for “July 1, 2010”.

    Subsec. (c)(2). [Pub. L. 111–152][/us/pl/111/152], § 1101(b)(1)(B), substituted “January 1, 2011, and December 31, 2011,” for “July 1, 2010, and ending on December 31, 2010,”.

----------

[Previous](./../../../../../../..//us/usc/t42/ch7/schXVIII/ptD/spt5/m__us_usc_t42_s1395w–152.md) | [Next](./../../../../../../..//us/usc/t42/ch7/schXVIII/ptD/spt5/m__us_usc_t42_s1395w–154.md) | [Root of Title](./../../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395w%E2%80%93153)

----------
----------

[/us/usc/t42/s1395w–102/e]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395w%E2%80%93102%2Fe
[/us/usc/t42/s1395w–114a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395w%E2%80%93114a
[/us/usc/t42/s1395w–114a/g/5]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs1395w%E2%80%93114a%2Fg%2F5
[/us/act/1935-08-14/ch531]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1935-08-14%2Fch531
[/us/pl/111/148/tIII]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F148%2FtIII
[/us/stat/124/461]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F124%2F461
[/us/pl/111/152/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F152%2FtI
[/us/stat/124/1037]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F124%2F1037
[/us/pl/111/152]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F152
[/us/pl/111/152]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F152


